Compliance with Tamoxifen and Arimidex in the adjuvant treatment of women with breast cancer

Objectives: The level of compliance for pharmacological therapies in chronic diseases varies, but is predominantly low. With Tamoxifen (TAM), 23% and 50% of non compliance after 1 and 4 years have been reported. No data on Anastrozol has yet been reported. The aim of this study was to evaluate the compliance rate in women with breast cancer on treatment with TAM or ANA. Materials and methods: We investigated a random sample of 100 postmenopausal women with breast cancer (50 TAM and 50 ANA) who have been operated in our hospital in 2004/2005 and thereafter have been assigned to an adjuvant endocrine treatment. We…